U.S. patent application number 15/901545 was filed with the patent office on 2018-07-05 for targeted modified il-1 family members.
The applicant listed for this patent is CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2, UNIVERSITEIT GENT, VIB VZW. Invention is credited to Sarah Gerlo, Frank Peelman, Jan Tavernier, Gilles Uze.
Application Number | 20180186894 15/901545 |
Document ID | / |
Family ID | 48874235 |
Filed Date | 2018-07-05 |
United States Patent
Application |
20180186894 |
Kind Code |
A1 |
Tavernier; Jan ; et
al. |
July 5, 2018 |
TARGETED MODIFIED IL-1 FAMILY MEMBERS
Abstract
The present disclosure relates to a modified Interleukin-1
(IL-1) family member cytokine, with reduced activity via its
cytokine receptor, wherein said interleukin-1 family member
cytokine is specifically delivered to target cells. Preferably, the
IL-1 family member cytokine is a mutant, more preferably it is a
mutant IL-1 with low affinity to the IL-1 receptor, wherein said
mutant IL-1 is specifically delivered to target cells. The
targeting is preferably realized by fusion of the modified IL-1
family member cytokine to a targeting moiety, preferably an
antibody or antibody-like molecule. The disclosure relates further
to the use of such targeted modified IL-1 family member cytokine to
treat diseases.
Inventors: |
Tavernier; Jan; (Balegem,
BE) ; Gerlo; Sarah; (Gent, BE) ; Peelman;
Frank; (Gentbrugge, BE) ; Uze; Gilles;
(Montpellier, FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
VIB VZW
UNIVERSITEIT GENT
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
UNIVERSITE MONTPELLIER 2
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER |
Gent
Gent
Paris
Montpellier
Montpellier |
|
BE
BE
FR
FR
FR |
|
|
Family ID: |
48874235 |
Appl. No.: |
15/901545 |
Filed: |
February 21, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14905352 |
Jan 15, 2016 |
9932409 |
|
|
PCT/EP2014/064283 |
Jul 4, 2014 |
|
|
|
15901545 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/569 20130101;
C07K 2317/22 20130101; C07K 16/2869 20130101; C07K 16/32 20130101;
C07K 16/40 20130101; A61P 37/04 20180101; A61K 2039/505 20130101;
A61P 35/00 20180101; C07K 14/545 20130101; C07K 2319/00
20130101 |
International
Class: |
C07K 16/40 20060101
C07K016/40; C07K 16/32 20060101 C07K016/32; C07K 14/545 20060101
C07K014/545; C07K 16/28 20060101 C07K016/28 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 19, 2013 |
EP |
13306047.5 |
Claims
1. A targeting construct, comprising a modified IL-1 family
cytokine characterized by a reduced affinity for its receptor, and
a targeting moiety.
2. The targeting construct, according to claim 1, wherein said
modified IL-1 family cytokine is a mutant IL-1 family cytokine.
3. The targeting construct according to claim 1 or 2, wherein said
targeting moiety is targeting to a marker expressed on a IL-1
family cytokine receptor expressing cell.
4. The targeting construct, according to claim 2, wherein said
mutant IL-1 family cytokine is a mutant IL-1.beta..
5. The targeting construct, according to claim 4, wherein said
targeting moiety is targeting to a marker expressed on an IL-1R1
and/or IL-1RacP expressing cell.
6. The targeting construct according to any of the preceding
claims, wherein said targeting moiety is directed to a tissue
specific marker.
7. The targeting construct according to any of the claims 1-5,
wherein said targeting moiety is directed to Her2.
8. The targeting construct according to any of the previous claims,
wherein said targeting moiety is an antibody.
9. The targeting construct according to claim 8, wherein said
antibody is a nanobody.
10. The targeting construct according to any of the preceding
claims, wherein the modified IL-1 family cytokine is an IL-1.beta.
mutant, selected from the group consisting of A117G/P118G,
R120GR120X, L122A, T125G/L126G, R127G, Q130X, Q131G, K132A,
S137G/Q138Y, L145G, H146X, L145A/L147A, Q148X, Q148G/Q150G,
Q150G/D151A, M152G, F162A, F162A/Q164E, F166A, Q164E/E167K,
N169G/D170G, 1172A, V174A, K208E, K209A K209X, K209A/K210A, K219X,
and E221KX, E221S/N224A, N224S/K225S, E244K and N245Q
11. A targeting construct according to any of the claims 1-10 for
use as a medicament.
12. The targeting construct according to any of the claims 1-10 for
use in stimulation of the immune response.
13. The targeting construct according to any of the claims 1-10 for
use in treatment of cancer.
Description
[0001] The present invention relates to a modified Interleukin-1
(IL-1) family member cytokine, with reduced activity via its
cytokine receptor, wherein said Interleukin-1 family member
cytokine is specifically delivered to target cells. Preferably, the
IL-1 family member cytokine is a mutant, more preferably it is a
mutant IL-1 with low affinity to the IL-1 receptor, wherein said
mutant IL-1 is specifically delivered to target cells. The
targeting is preferably realized by fusion of the modified IL-1
family member cytokine to a targeting moiety, preferably an
antibody or antibody-like molecule. The invention relates further
to the use of such targeted modified IL-1 family member cytokine to
treat diseases.
[0002] The Interleukin-1 (IL-1) family consists of 11 structurally
related family members (IL-1.alpha., IL-1-.beta., IL-1Ra, IL-18,
IL-33 and IL-1F5 to IL-1 F10), that are among the most potent
immune system signaling molecules, acting through a group of
closely related receptors. All IL-1 receptors have a similar mode
of activation: upon binding of ligand to the primary receptor
subunit (i.e. IL-1R1 for IL-1.alpha. and .beta., IL-18R for IL-18
and ST2 for IL-33), a second receptor subunit is recruited (i.e.
IL-1RAP for IL-1.alpha. and .beta., IL-18RAP for IL-18 and IL-1RAP
for IL-33) and signalling is initiated via juxtaposition of the
receptor subunits' cytoplasmic Toll/IL-1 receptor (TIR) domains.
The dimerized TIR domains provide a docking platform for the MYD88
adaptor protein, which via recruitment of other intermediates leads
to activation of the pro-inflammatory nuclear factor-.kappa.B
(NF-.kappa.B) and mitogen-activated protein kinase (MAPK) pathways.
The IL-1 family members are primarily produced by innate immune
cells and act on a variety of cell types during the immune response
(for review see Sims and Smith, 2010).
[0003] T lymphocytes are one of the main IL-1 family target cells
and the potentiating effects of in particular IL-1.alpha. and
IL-1.beta. on the expansion and differentiation of different T cell
subsets, in particular CD8+ T cells (Ben-Sasson, 2011; Ben-Sasson,
2013) and Th17 cells (Sutton et al., 2006; Acosta-Rodriguez et al.,
2007; Dunne et al., 2010; Shaw et al., 2012) have been firmly
established. Th17 cells are characterized by the production of
IL-17 and play an important role in auto-immune disease and chronic
inflammation (reviewed in Wilke et al., 2011). Among T cell
subsets, Th17 cells express the highest levels of the IL-1R and
IL-1 plays an important role in Th17 priming.
[0004] IL-18 is best known as an IFN.gamma.-inducing cytokine with
a potent action on Th1 cells and natural killer (NK) cells, on
(Okamura et al., 1995; Takeda et al. 1998). In addition, IL-18
enhances neutrophil function (Leung et al., 2001). Several reports
demonstrate IL-18 anti-tumour action in animal models (Micallef et
al., 1997; Loeffler et al., 2008; Wigginton et al., 2002; Zaki et
al., 2010) and recombinant human IL-18 therapy recently entered
clinical trials to evaluate its efficacy for treatment of advanced
cancer (Robertson et al., 2008). As opposed to IL-18, IL-33 acts
primarily on Th2 cells (Schmitz et al., 2005) and mast cells
(Allakhverdi et al., 2007), and recently was shown to act on CD8+T
cells to drive antiviral responses (Bonilla et al., 2012). The
other IL-1 family members are less well characterized, but in
summary different IL-1 family members have specificities for
different T-cell subsets or other cell types and hence different
therapeutic applications.
[0005] Besides having indirect anti-tumour activity, via activation
of T and NK cells, IL-1 family members were shown to have direct
cytostatic properties, which were most convincingly demonstrated on
human melanoma cells (Morinaga et al., 1990; Usui et al., 1991;
Rangnekar et al., 1992).
[0006] In view of the contribution of several IL-1 family members
to inflammatory processes, clinical interest has been mainly
oriented towards the development of IL-1-antagonizing strategies
(Dinarello et al., 2012). Nevertheless, exploitation of controlled
agonistic IL-1 activity could have applications in different
physiological/pathological processes, where immunostimulatory
effects would be desirable. One of the main concerns regarding the
use of IL-1 in immunostimulatory therapies, is its severe toxicity
when administered systemically. However, when IL-1 action could be
confined to a selected cellular population, the toxicity issue
might be resolved, which opens up therapeutic perspectives.
[0007] For instance, although there has been a lot of interest on
blocking Th17 responses in view of their pathogenic role in
auto-immune conditions such as multiple sclerosis, rheumatoid
arthritis and inflammatory bowel disease (Wilke et al., 2011),
normal Th17 function is indispensable for protective immunity
against a range of pathogens, including Mycobacterium tuberculosis
(Khader et al., 2007), Klebsiella pneumoniae (Ye et al., 2001) and
Bordetella pertussis (Higgins et al., 2006). As IL-1.beta.
stimulates Th17 function, the idea has been raised to use
IL-1.beta. as a T-cell adjuvant to enhance the response to weak
vaccines (Ben-Sasson et al., 2011). Other applications could be the
targeting of IL-1.beta. or IL-33 to the CD8+ T-cell population to
enhance antiviral responses or targeting IL-18 to Th1 cells or NK
cells to promote anti-tumor activity.
[0008] Surprisingly we found that it is possible to design IL-1
family modifications that are defective in activating their
receptor, but, when fused to a targeting moiety, regain their
activity on selected cell types by a concentration effect at the
cell surface. The IL-1 mutants have a reduced affinity for their
cognate receptors, and hence are unable to efficiently bind and
activate their receptors. However, by fusing them to a targeting
moiety (such as a nanobody) the activity of the mutant IL-1 family
member is restored on cells expressing the cell surface target,
recognized by the targeting moiety. Because the activation is
confined to the selected targeted cell types only, no major
systemic toxicity occurs.
[0009] A first aspect of the invention is a targeting construct,
comprising a modified IL-1 family member cytokine, characterized by
a reduced affinity for its cytokine receptor, and a targeting
moiety. IL-1 family member cytokines are known to the person
skilled in the art, and include, but are not limited to
IL-1.alpha., IL-1.beta., IL-1Ra, IL18, IL-36Ra, IL-36.alpha.,
IL-37, IL-36.beta., IL-36.gamma., IL-38 and IL-33 (also indicated
as IL-1F1, IL-1F2, IL-1F3, IL-1F4, IL-1F5, IL-1F6, IL-1F7, IL-1F8,
IL-1F9, IL-1F10 and IL-1F11, respectively). Fora review on the IL-1
family, see Dinarello (2011). A modified IL-1 family cytokine means
that the IL-1 family cytokine has been changed to alter the
affinity to its receptor, with as final result that the modified
IL-1 family cytokine has a reduced affinity for the receptor and a
consequent reduced biological activity, as compared to the
endogenous wild type cytokine that binds normally to the receptor.
Such a modification can be a modification that decreases the
activity of the normal wild type cytokine, or it can be a
modification that increases the affinity of a homologous,
non-endogenous IL-1 family cytokine (such as, but not limited to a
IL-1 family cytokine of another species that is not active on a
human IL-1 family cytokine receptor). Modifications can be any
modification reducing or increasing the activity, known to the
person skilled in the art, including but not limited to chemical
and/or enzymatic modifications such as pegylation and
glycosylation, fusion to other proteins and mutations. Preferably
said modification is a mutation, even more preferably it is a
mutation decreasing the affinity of the IL-1 family cytokine. A
reduced affinity and a consequent reduced biological activity as
used here means that the modified IL-1 family cytokine has a
biological activity of less than 70% of the biological activity of
the IL-1 family cytokine, even more preferably less than 60% of the
biological activity of the IL-1 family cytokine, more preferably
less than 50% of the biological activity of the IL-1 family
cytokine, more preferably less than 40% of the biological activity
of the IL-1 family cytokine, more preferably less than 30% of the
biological activity of the IL-1 family cytokine, more preferably
less than 20% of the biological activity of the IL-1 family
cytokine, more preferably less than 10% of the biological activity
of the IL-1 family cytokine, most preferably less than 1% of the
biological activity of the IL-1 family cytokine as compared to the
IL-1 family cytokine that normally binds to the receptor.
Preferably, the modified IL-1 family cytokine is a mutant of the
wild type IL-1 family cytokine and the activity is compared with
the wild type IL-1 family cytokine. The affinity and/or the
activity can be measured by any method known to the person skilled
in the art.
[0010] A preferred embodiment of the invention is a targeting
construct, comprising a mutant IL-1.beta. characterized by reduced
affinity for the Interleukin-1 receptor type I (IL-1RI) and/or the
interleukin-1 receptor accessory protein (IL-1RAcP) receptor, and a
targeting moiety. A mutant IL-1.beta. as used here can be any
mutant form that has a lower affinity for the receptor and as a
consequence a reduced activation of the proinflammatory
transcription factor NF.kappa.B. The affinity of the mutant
IL-1.beta. to the receptor, in comparison to the affinity of the
wild type IL-1.beta. to the receptor can be measured by Scatchard
plot analysis and computer-fitting of binding data (e.g. Scatchard,
1949) or by reflectometric interference spectroscopy under flow
through conditions, as described by Brecht et al. (1993). The
activity of the mutant IL-1.beta. is typically measured using a
bioassay (for example by the induction of cell death) or by
measuring signaling events downstream of the receptor. Such
signaling events can be the modification or nuclear translocation
of NF-.kappa.B, or the induction of a selected reporter gene. The
mutant may be a point mutant, a deletion or an insertion mutant, or
a combination thereof; several mutations may be present in one
protein. Preferably, said mutant IL-1.beta. is obtained by active
mutagenesis, such as, but not limited to site directed mutagenesis
by polymerase chain reaction amplification. Preferably, said mutant
IL-1.beta. has a biological activity of less than 70% of the
biological activity of the wild type IL-1.beta., even more
preferably less than 60% of the biological activity of the wild
type IL-1.beta., more preferably less than 50% of the biological
activity of the wild IL-1.beta., more preferably less than 40% of
the biological activity of the wild IL-1.beta., more preferably
less than 30% of the biological activity of the wild IL-1.beta.,
more preferably less than 20% of the biological activity of the
wild IL-1.beta., more preferably less than 10% of the biological
activity of the wild type, most preferably less than 1% of the wild
type of which it is deduced (i.e. the wild type IL-1.beta. of which
the coding sequence has been mutated to obtain the mutant
IL-1.beta.). Preferably, said mutant is a mutant selected from the
group consisting of A117G/P118G, R120X, L122A, T125G/L126G, R127G,
Q130X, Q131G, K132A, S137G/Q138Y, L145G, H146X, L145A/L147A, Q148X,
Q148G/Q150G, Q150G/D151A, M152G, F162A, F162A/Q164E, F166A,
Q164E/E167K, N169G/D170G, 1172A, V174A, K208E, K209X, K209A/K210A,
K219X, E221X, E221S/N224A, N224S/K225S, E244K, N245Q (wherein X can
be any change in amino acid, preferably a non-conservative change).
Even more preferably said mutation is selected from the group
consisting of R120A, R120G, Q130A, Q130W, H146A, H146G, H146E,
H146N, H146R, Q148E, Q148G, Q148L, K209A, K209D, K219S, K219Q,
E221S and E221K. Most preferably said mutation is selected from the
group consisting of R120G, H146N, H146R, Q148E, Q148G and K209A.
(numbering base on the human IL-1(3 sequence, genbank accession
number NP_000567, version NP-000567.1, GI: 10835145).
[0011] Preferred regions for mutations for IL-18 are Y37-K44,
R49-Q54, D59-R63, E67-C74, R80, M87-A97, N127-K129, Q139-M149,
K165-K171, R183 and Q190-N191. Most preferred are the regions
E67-C74 and M87-A97 (numbering based on the human sequence, genbank
accession number AAV38697, version AAV38697.1, GI: 54696650) .
[0012] Preferred regions for mutations for IL-33 are I113-Y122,
S127-E139, E144-D157, Y163-M183, E200, Q215, L220-C227 and
T260-E269 (numbering based on the human sequence, genbank accession
number NP_254274, version NP_254274.1, GI:15559209)
[0013] Preferably, said targeting moiety is targeting to a marker
expressed on an IL-1.beta. receptor expressing cell, preferably a
cell expressing IL1-RI. In one preferred embodiment, said targeting
moiety is directed to a tissue specific marker.
[0014] The modified IL-1 family member is linked to a targeting
moiety. "Linked" as used here may be by a covalent binding, or it
may be by an affinity binding. A "targeting moiety" as used here is
a binding molecule that can direct the fusion protein towards a
binding site on a cell that is expressing a receptor for the IL-1
family member, by specific interaction between the binding site and
the binding molecule. In one preferred embodiment, said binding
molecule is a small compound, specifically binding to a molecule
situated on the outside of the cell. In another preferred
embodiment, said molecule is a sugar structure, directed towards a
lectin-like molecule expressed on the cell wall. In another
preferred embodiment said binding molecule is a peptide, targeting
the tumor or inflammation environment. Such peptides are known to
the person skilled in the art, and include, but are not limited to
NGR and RGD peptides (Yang et al., 2011; WO2005054293). In still
another preferred embodiment, said binding molecule is a protein
comprising a binding domain. This includes, but is not limited to
carbohydrate binding domains (CBD) (Blake et al, 2006), lectin
binding proteins, heavy chain antibodies (hcAb), single domain
antibodies (sdAb), minibodies (Tramontano et al., 1994), the
variable domain of camelid heavy chain antibodies (VHH), the
variable domain of the new antigen receptors (VNAR), affibodies
(Nygren et al., 2008), alphabodies (WO2010066740), designed
ankyrin-repeat domains (DARPins) (Stumpp et al., 2008), anticalins
(Skerra et al., 2008), knottins (Kolmar et al., 2008) and
engineered CH2 domains (nanoantibodies; Dimitrov, 2009).
Preferably, said targeting moiety consists of a single polypeptide
chain and is not post-translationally modified. Even more
preferably, said targeting moiety is a nanobody.
[0015] The targeting moiety can be any targeting moiety known to
the person skilled in the art. In a non-limiting example, said
targeting moiety may be a bispecific antibody, directed to a
binding site on the target cell for one specificity, and to the
targeted cytokine, or to a tag fused to said cytokine for the other
specificity. In another non-limiting example, the targeting moiety
may be chemically linked to the mutant Interleukin-1, or it may be
a recombinant fusion protein. Preferably, said targeting construct
is a recombinant fusion protein. The targeting moiety may be fused
directly to the mutant IL-1.beta., or it may be fused with the help
of a linker fragment, preferably a GGS linker. The targeting moiety
may be fused at the aminoterminal or at the carboxyterminal end of
the mutated IL-1.beta.; preferably said targeting moiety is fused
at the carboxyterminal extremity of the mutated IL-1.beta.
molecule. The targeting construct may further comprise other
domains such as, but not limited to a tag sequence, a signal
sequence, another cytokine or an antibody.
[0016] Another aspect of the invention is a targeting construct
according to the invention for use as a medicament. One preferred
embodiment is a targeting construct according to the invention for
use in stimulation of the immune response. Indeed, it is know that
IL-1 treatment can induce antigen expression on B-cells (Killer et
al., 1989); likewise, IL-18 treatment is augmenting cellular and
humoral immunities (Kinoshita et al., 2011). In a similar way, it
has been demonstrated that IL-1 acts on T-cells to enhance the
magnitude of in vivo immune responses (Ben-Sasson et al., 2011; Ben
Sasson et al., 2013). Therefore, one preferred aspect of the
invention is the targeting construct according to the invention for
use as an adjuvant in vaccination. The targeting construct
according to the invention is especially interesting in this
respect, as the pro-inflammatory effect of normal wild type IL-1
makes the application of IL-1 as such impossible.
[0017] Still another aspect of the invention is a targeting
construct according to the invention for use in treatment of
cancer. Indeed, Morinaga et al., 1990, Usui et al., 1991and
Rangnekar et al., 1992 have shown that IL-1 family members do have
direct cytostatic properties, which were most convincingly
demonstrated on human melanoma cells.
BRIEF DESCRIPTION OF THE FIGURES
[0018] FIG. 1: Schematic representation of the IL-1.beta.-nanobody
fusion proteins
[0019] FIG. 2: Concentration dependency of the induction of the
NF.kappa.B activity by wild type and mutant Q148G IL-1 Her2
nanobody fusions (A) and other selected mutants (B), in mock
transfected cells, or cells transfected with signaling deficient
Her2.
[0020] FIG. 3: Effect of wild type and mutant (Q148G, L145A/L147A,
F162A/Q164E) IL-1 Her2 nanobody fusions on nuclear translocation of
endogenous NF-.kappa.B p65 in mock transfected cells, or cells
transfected with signaling deficient Her2.
[0021] FIG. 4: Induction of the NF.kappa.B activity by wild type
and 5 different IL-1 mutants, fused to an anti-murine leptin
receptor nanobody, on cells expressing the murine leptin receptor
(mLR) or not (no mLR).
[0022] FIG. 5: Concentration dependency of the induction of the
NF.kappa.B activity by ILA double mutants fused to the Her2
nanobody in mock transfected cells, or cells transfected with
signaling deficient Her2.
EXAMPLES.
[0023] Materials and Methods to the Examples
[0024] Cloning of IL-1-Nanobody Fusion Proteins.
[0025] The 4-10 nanobody directed against the murine leptin
receptor is described in Zabeau et al. (2012) and in the patent WO
2006/053883. The anti-Her2 nanobody 1R59B is described in Vaneycken
et al. (2011). Both nanobodies were cloned with a C-terminal His
tag in the pMET7 eukaryotic expression vector. A codon-optimized
sequence encoding the mature IL-1.beta. protein, preceded by the
SigK leader peptide, and equipped with an N-terminal HA tag, was
generated via gene synthesis (Invitrogen Gene Art). To generate the
IL-1.beta.-nanobody fusion proteins, the IL-1.beta. sequence was
cloned 5' to the nanobody sequence in pMet7, with a 13.times.GGS
linker separating the cytokine and nanobody moieties. (FIG. 1)
[0026] IL-1.beta. Mutants.
[0027] IL-1.beta. mutants expected to have reduced binding affinity
for the IL-1R were selected based on literature and analysis of
published crystal structures of human IL-1.beta. complexed with its
receptor. Mutations in the hIL-1.beta. moiety were created via
site-directed mutagenesis (QuickChange, Stratagene) using the
mutagenesis primers as indicated in table I:
TABLE-US-00001 TABLE I mutants and primers used Fw primer Rev
primer 1 A117G/ CCGACTACGCTGGCGGCAGTGACGGTGTCA
GCAGTTCAGGCTTCTGACACCGTCACTG P118G GAAGCCTGAACTGC CCGCCAGCGTAGTCGG
2 R120A CTGGCGGCAGCGCCCCTGTCGCTAGCCTGA CGCAGGGTGCAGTTCAGGCTAGCGACA
ACTGCACCCTGCG GGGGCGCTGCCGCCAG 3 R120G
GCGGCAGCGCCCCTGTCGGAAGCTTGAACT GCAGGGTGCAGTTCAAGCTTCCGACAG
GCACCCTGC GGGCGCTGCCGC 4 L122A CGCTGGCGGCAGTGCCCCTGTCAGAAGCGC
GCTGTCCCGCAGGGTGCAGTTCGCGCT GAACTGCACCCTGCGGGACAGC
TCTGACAGGGGCACTGCCGCCAGCG 5 T125G/ CGCCCCTGTCAGAAGCCTGAACTGCGGCGG
GCTTTTCTGCTGGCTGTCCCGGCCGCC L126 GCCGGGACAGCCAGCAGAAAAGC
GCAGTTCAGGCTTCTGACAGGGGCG 6 R127G AGAAGCCTGAACTGCACACTGGGGGACAGC
GACCAGGCTTTTCTGCTGGCTGTCCCCC CAGCAGAAAAGCCTGGTC
AGTGTGCAGTTCAGGCTTCT 7 Q130A CCCTGCGGGACAGCGCGCAGAAAAGCCTGG
CCAGGCTTTTCTGCGCGCTGTCCCGCA GGG 8 Q130W
CTGCACCCTGCGGGACAGCTGGCAGAAAAG GCTCATGACCAGGCTTTTCTGCCAGCTG
CCTGGTCATGAGC TCCCGCAGGGTGCAG 9 Q131G
CTGCGGGACAGCCAGGGGAAGAGCCTGGTC CGCTCATGACCAGGCTCTTCCCCTGGCT ATGAGCG
GTCCCGCAG 10 K132A GCACCCTGCGGGACAGCCAGCAGGCTAGCC
GGCCGCTCATGACCAGGCTAGCCTGCT TGGTCATGAGCGGCC GGCTGTCCCGCAGGGTGC 11
S137G/ CAGCAGAAAAGCCTGGTCATGGGGTACCCCT GCAGTGCCTTCAGCTCGTAGGGGTACC
Q138Y ACGAGCTGAAGGCACTGC CCATGACCAGGCTTTTCTGCTG 12 L145G
GCCCCTACGAGCTGAAGGCAGGTCATCTGCA CCATGTCCTGGCCCTGCAGATGACCTG
GGGCCAGGACATGG CCTTCAGCTCGTAGGGGC 13 H146A
CGAGCTGAAGGCACTGGCTCTTCAGGGCCA CCATGTCCTGGCCCTGAAGAGCCAGTG GGACATGG
CCTTCAGCTCG 14 H146G CCTACGAGCTGAAGGCACTGGGTCTGCAGG
CCATGTCCTGGCCCTGCAGACCCAGTG GCCAGGACATGG CCTTCAGCTCGTAGG 15 M146E
GCTGAAGGCACTGGAGCTGCAGGGCCAGG CCTGGCCCTGCAGCTCCAGTGCCTTCA GC 16
H146N AGCTGAAGGCACTGAATCTGCAGGGCCAG CTGGCCCTGCAGATTCAGTGCCTTCAGC T
17 H146R CTGAAGGCACTGCGTCTGCAGGGCCAG CTGGCCCTGCAGACGCAGTGCCTTCAG 18
L145A/ GCGGCCCCTACGAGCTGAAGGCAGCGCATG CCATGTCCTGGCCCTGCGCATGCGCTG
L147A CGCAGGGCCAGGACATGG CCTTCAGCTCGTAGGGGCCGC 19 Q148E
GGCACTGCATCTGGAGGGCCAGGACAT ATGTCCTGGCCCTCCAGATGCAGTGCC 20 Q148G
GAAGGCACTGCATCTGGGTGGCCAGGACAT GCTGTTCCATGTCCTGGCCACCCAGATG
GGAACAGC CAGTGCCTTC 21 Q148L GCACTGCATCTGCTGGGCCAGGACATG
CATGTCCTGGCCCAGCAGATGCAGTGC 22 Q148G/
CGAGCTGAAGGCACTGCATCTGGGGGGCGG CCTGCTGTTCCATGTCCCCGCCCCCCA Q150G
GGACATGGAACAGCAGG GATGCAGTGCCTTCAGCTCG 23 Q150G/
GCACTGCATCTGCAGGGCGGGGCCATGGAA GCTGAACACGACCTGCTGTTCCATGGCC D151A
CAGCAGGTCGTGTTCAGC CCGCCCTGCAGATGCAGTGC 24 M152G
GCACTGCATCTGCAGGGCCAGGACGGGGAA GCTCATGCTGAACACCACCTGCTGTTCC
CAGCAGGTGGTGTTCAGCATGAGC CCGTCCTGGCCCTGCAGATGCAGTGC 25 F162A
CATGGAACAGCAGGTGGTGTTCAGCATGAGC GTCGTTGCTTTCCTCGCCCTGCACGGC
GCCGTGCAGGGCGAGGAAAGCAACGAC GCTCATGCTGAACACCACCTGCTGTTCC ATG 26
F162A/ GCAGGTCGTGTTCAGCATGAGCGCCGTGGA GGATCTTGTCATTGCTTTCCTCGCCCTC
Q164E GGGCGAGGAAAGCAATGACAAGATCC CACGGCGCTCATGCTGAACACGACCTG C 27
F166A CCGACTTCACCATGCAGGCCGTCTCCAGCGG CCAGATCTGCTGCCGCCGCTGGAGACG
CGGCAGCAGATCTGG GCCTGCATGGTGAAGTCGG 28 Q164E/
GCATGAGCTTCGTGGGGGGCAAGGAAAGCA GGCCACGGGGATCTTGTCATTGCTTTCC E167K
ATGACAAGATCCCCGTGGCC TTGCCCCCCACGAAGCTCATGC 29 N169G/
GCAGGGCGAGGAAAGCGGCGGCAAGATCCC CTTCTCTTTCAGGCCTAGGGCCACGGG D170G
CGTGGCCCTAGGCCTGAAAGAGAAG GATCTTGCCGCCGCTTTCCTCGCCCTGC 30 I172A
GAAAGCAACGACAAGGCCCCCGTGGCCCTG CCCAGGGCCACGGGGGCCTTGTCGTTG GG CTTTC
31 V174A GCAACGACAAGATCCCCGCGGCCCTGGGCC CTTTCAGGCCCAGGGCCGCGGGGATCT
TGAAAG TGTCGTTGC 32 K208E GCAGCTGGAAAGCGTGGATCCCAAGAACTAC
GCGTTTTTCCATCTTTTTCTCGGGGTAGT CCCGAGAAAAAGATGGAAAAACGC
TCTTGGGATCCACGCTTTCCAGCTGC 33 K209A CCCCAAGAACTACCCCAAGGCAAAGATGGAA
GTTGAACACGAAGCGCTTTTCCATCTTT AAGCGCTTCGTGTTCAAC
GCCTTGGGGTAGTTCTTGGGG 34 K209D GCAGCTGGAAAGCGTGGATCCCAAGAACTAC
GCGTTTTTCCATCTTGTCCTTGGGGTAG CCCAAGGACAAGATGGAAAAACGC
TTCTTGGGATCCACGCTTTCCAGCTGC 35 K209A/
CCCCAAGAACTACCCCAAGGCAGCGATGGAA GAACACGAAGCGTTTTTCCATCGCTGCC K210A
AAACGCTTCGTGTTC TTGGGGTAGTTCTTGGGG 36 K219S
AAAAACGCTTCGTGTTCAACAGCATCGAGAT GAGCTTGTTGTTGATCTCGATGCTGTTG
CAACAACAAGCTC AACACGAAGCGTTTTT 37 K219Q
AAAAACGCTTCGTGTTCAACCAGATCGAGAT CTTGTTGTTGATCTCGATCTGGTTGAAC
CAACAACAAG ACGAAGCGTTTTT 38 E221S GCTTCGTGTTCAACAAGATCTCGATCAACAAC
ACTCGAGCTTGTTGTTGATCGAGATCTT AAGCTCGAGT GTTGAACACGAAGC 39 E221K
CTTCGTGTTCAACAAGATCAAGATCAACAACA TCGAGCTTGTTGTTGATCTTGATCTTGTT
AGCTCGA GAACACGAAG 40 K219S/ GGAAAAACGCTTCGTCTTCAACAGCATCTCG
CGAACTCGAGCTTGTTGTTGATCGAGAT E221S ATCAACAACAAGCTCGAGTTCG
GCTGTTGAAGACGAAGCGTTTTTCC 41 E221S/ CGCTTCGTGTTCAACAAGATCTCGATCAACG
CTCGAACTCGAGCTTGGCGTTGATCGAG N224A CCAAGCTCGAGTTCGAG
ATCTTGTTGAACACGAAGCG 42 N224S/ CAACAAGATCGAGATCAACAGCAGCCTCGAA
CTGGGCGCTCTCGAATTCGAGGCTGCT K225S TTCGAGAGCGCCCAG
GTTGATCTCGATCTTGTTG 43 E244K CCCCAACTGGTACATCAGTACTAGTCAGGCC
GGAACACGGGCATATTCTTGGCCTGACT AAGAATATGCCCGTGTTCC
AGTACTGATGTACCAGTTGGGG 44 N245Q CAGCACTAGTCAGGCCGAGCAGATGCCCGT
GGTGCCGCCCAGGAAGACGGGCATCTG CTTCCTGGGCGGCACC CTCGGCCTGACTAGTGCTG 45
E244K/ CATCAGCACTAGTCAGGCCAAGCAGATGCCC GGTGCCGCCCAGGAAGACGGGCATCTG
N245Q GTCTTCCTGGGCGGCACC CTTGGCCTGACTAGTGCTGATG 46* R120G
GCGGCAGCGCCCCTGTCGGAAGCTTGAACT GCAGGGTGCAGTTCAAGCTTCCGACAG Q131G
GCACCCTGC GGGCGCTGCCGC 47* R120G/ CGAGCTGAAGGCACTGGCTCTTCAGGGCCA
CCATGTCCTGGCCCTGAAGAGCCAGTG H146A GGACATGG CCTTCAGCTCG 49* R120G/
GCGGCCCCTACGAGCTGAAGGCAGCGCATG CCATGTCCTGGCCCTGCGCATGCGCTG L145A/
CGCAGGGCCAGGACATGG CCTTCAGCTCGTAGGGGCCGC L147A 48** R120G/
GCGGCAGCGCCCCTGTCGGAAGCTTGAACT GCAGGGTGCAGTTCAAGCTTCCGACAG Q148G
GCACCCTGC GGGCGCTGCCGC 50* R120G/ GCAGGTCGTGTTCAGCATGAGCGCCGTGGA
GGATCTTGTCATTGCTTTCCTCGCCCTC F162A/ GGGCGAGGAAAGCAATGACAAGATCC
CACGGCGCTCATGCTGAACACGACCTG Q164E C 51* R120G/
GCAGCTGGAAAGCGTGGATCCCAAGAACTAC GCGTTTTTCCATCTTTTTCTCGGGGTAGT K208E
CCCGAGAAAAAGATGGAAAAACGC TCTTGGGATCCACGCTTTCCAGCTGC 52** Q131G/
CTGCGGGACAGCCAGGGGAAGAGCCTGGTC CGCTCATGACCAGGCTCTTCCCCTGGCT Q148G
ATGAGCG GTCCCGCAG 53** Q148G/ GCAGGTCGTGTTCAGCATGAGCGCCGTGGA
GGATCTTGTCATTGCTTTCCTCGCCCTC F162A/ GGGCGAGGAAAGCAATGACAAGATCC
CACGGCGCTCATGCTGAACACGACCTG Q164E C 54** Q148G/
GCAGCTGGAAAGCGTGGATCCCAAGAACTAC GCGTTTTTCCATCTTTTTCTCGGGGTAGT K208E
CCCGAGAAAAAGATGGAAAAACGC TCTTGGGATCCACGCTTTCCAGCTGC
*double/triple-mutants were created using R120G as template.
**double/triple-mutants were created using Q148G as template.
[0028] Production of IL-1.beta. Fusion Proteins.
[0029] IL-1.beta. fusion proteins were produced in HEK293T cells.
For small-scale production, HEK293T cells were seeded in 6-well
plates at 400000 cells/well in DMEM supplemented with 10% FCS.
After 24 hours, culture medium was replaced by medium with reduced
serum (DMEM/5% FCS) and cells were transfected using linear PEI.
Briefly, PEI transfection mix was prepared by combining 1 .mu.g
expression vector with 5 .mu.g PEI in 160 .mu.l DMEM, incubated for
10 minutes at RT and added to the wells dropwise. After 24 hours,
transfected cells were washed with DMEM and layered with 1.5 ml
OptiMem/well for protein production. Conditioned media were
recuperated after 48 hours, filtered through 0.45 p filters and
stored at -20.degree. C. IL-1.beta. content in the conditioned
media was determined by Elisa according to the manufacturer's
instructions (R&D Systems).
[0030] NF-.kappa.B Reporter Gene Assay.
[0031] To assess IL-1R activation, we used HEK-Blue.TM. IL-1.beta.
cells that stably express the IL-1R (Invivogen) and transfected
them transiently with an NF-.kappa.B luciferase reportergene.
Briefly, HEK-Blue.TM. IL-1.beta. cells were seeded in culture
medium (DMEM/10% FCS) in 96-well plates (10000 cells/well) and
transfected the next day using the calciumphosphate precipitation
method with the indicated amounts of expression plasmids and 5
ng/well of the 3.kappa.B-Luc reportergene plasmid (Vanden Berghe et
al., 1998). 24 hours post-transfection, culture medium was replaced
by starvation medium (DMEM) and 48 hours post-transfection, cells
were induced for 6 hours with fusion proteins. After induction,
cells were lysed and luciferase activity in lysates was determined
using the Promega Firefly Luciferase Assay System on a Berthold
centro LB960 luminometer.
[0032] Analysis of NF-.kappa.B Nuclear Translocation via Confocal
Microscopy.
[0033] For confocal imaging, 10.sup.5 HEK293-T cells/well (in
6-well plate) were seeded on glass coverslips (Zeiss), coated with
poly-L-lysine (Sigma). The next day, cells were transfected with
200 ng/well of empty vector or HER2.DELTA.cyt expression plasmid
using the calcium phosphate precipitation method. After 48 hours,
cells were treated for 30 minutes with vehicle (medium) or IL1-Her2
nanobody fusion protein (10 ng/ml). Next, cells were rinsed with
1.times.PBS and fixed for 15 minutes at room temperature in 4%
paraformaldehyde. After three washes with 1.times.PBS, cells were
permeabilized with 0.1% Triton X-100 in 1.times.PBS for 10 minutes
and blocked in 1% BSA in 1.times.PBS for another 10 minutes at room
temperature. Samples were then incubated for 1 hour at 37.degree.
C. with rabbit anti-p65 antibody (Santa Cruz C20, diluted 1:800)
and mouse anti-Flag Antibody (Sigma M2, 1:2000). After four washes
in 1.times.PBS, cells were incubated for 1 hour at room temperature
with anti-rabbit Alexa 488 and anti-mouse Alexa 594
fluorochrome-conjugated secondary antibodies (both diluted 1:800).
After secondary antibody incubation, cells were washed four times
in 1.times.PBS and nuclei were stained with DAPI (2 .mu.g/ml).
After a final wash step in 1.times.PBS, coverslips were mounted
using propyl gallate. Images were acquired using a 60.times.1.35 NA
objective on an Olympus IX-81 laser scanning confocal microscope
and analyzed using Fluoview 1000 software.
Example 1
IL-1.beta.-Ligand and IL-1.beta.-Nanobody Fusion Proteins
[0034] FIG. 1 shows a scheme of the IL-1.beta.-nanobody fusion
proteins constructed with either WT hIL-1.beta. or the hIL1.beta.
mutants described in table I.
Example 2
IL-1.beta. Activity of Selected Mutant IL-1.beta.-Nanobody Fusions
is Restored on Cells Expressing the Nb Targets
[0035] Wild type IL-1.beta. and 45 IL-1.beta. mutants (Table I)
were fused to a well-characterized nanobody recognizing Her2 (1
R59B). The IL-1.beta.-nanobody fusion proteins were tested on
HEK-Blue.TM. IL-1.beta. cells, transiently transfected with an
NF-.kappa.B reportergene plasmid (5 ng/well) and a Her2.DELTA.cyt
(signalling-deficient) expression plasmid (2 ng/well). Cells were
treated for 6 hours with IL-1.beta.-Her2 nanobody fusions (dose
response ranging from 0.4 to 250 ng/ml). As demonstrated in FIG.
2A, the IL-1.beta.-Q148G-Her2 nanobody fusion displayed a reduced
ability to activate NF-.kappa.B as compared to the WT
IL1-.beta.-Her2 nanobody fusion. Importantly, targeting of the
Q148G mutant to Her2.DELTA.cyt-expressing cells restored its
activity and produced a dose-response curve for NF-.kappa.B
activation that perfectly parallels that of the WT IL-1.beta. on
mock-transfected cells. Also evident from this figure is a strong
targeting effect for the WT IL-1.beta. Her2 nanobody fusion.
Similar "activation by targeting" effects were observed for six
other IL-1.beta. mutants (R120G, Q131G, H146A, H145A/L147A,
F162A/Q164E and K208E) fused to the Her2 nanobody (FIG. 2B).
[0036] To obtain further proof for the "activation by targeting"
concept, we next explored whether we could visualize the selective
activation of NF-.kappa.B in Her2-expressing cells by the
IL-1.beta.-Her2 nanobody fusions via confocal microscopy. We
measured activation of endogenous NF-KB by assaying its nuclear
translocation. As evident from FIG. 3, only the WT IL-1.beta.-Her2
nanobody fusion promoted translocation of endogenous NF-.kappa.B in
cells that do not express Her2. Whereas they did not promote
detectable NF-.kappa.B translocation in mock-transfected cells, the
three tested mutant IL1-.beta.-Her2 nanobody fusions triggered
NF-.kappa.B nuclear translocation in cells that also stained
positive for Her2, indicating they only act on targeted cells.
[0037] To evaluate whether the "activation by targeting" concept
also works using a nanobody to an unrelated membrane protein, we
fused WT IL-1.beta. and five of the disabled IL-1.beta. mutants
(R120G, Q131G, H146A, Q148G, K209A) to a previously characterized
nanobody recognizing the mLR (4-10). An experiment similar to that
reported for the IL-1.beta.-Her2 nanobody fusion (FIG. 2) was
performed using HEK-Blue.TM. IL-1.beta. cells, transiently
transfected with a mLR expression plasmid (10 ng/well). Similar to
the results obtained with the Her2 nanobody fusion proteins, all
investigated mutant IL-1.beta. nanobody fusions (tested at 12.5
ng/ml) showed a reduced ability, as compared to the WT fusion, to
activate NF-.kappa.B on cells that do not express mLRs. However,
targeting by the mLR nanobody moiety partially restored the
activity of the selected mutants (FIG. 4).
[0038] Because the IL-1.beta. mutants described above retained
significant residual biological activity, we combined different
mutations to obtain double/triple mutants with reduced basal
activity. Nine double/triple mutants were tested (cf. table I
mutants 46 to 54) and from these, six mutant proteins (Q131G/Q148G,
Q148G/K208E, R120G/Q131G, R120G/Q131G, R120G/H146A, R120G/K208E,
R120G/F162A/Q164E) displayed no residual activity (using the same
assay for measuring NF-.kappa.B as in FIG. 2) on Her2-negative
cells, whilst partially restored activity was apparent on cells
overexpressing Her2.DELTA.cyt (FIG. 5).
[0039] These data altogether indicate that targeting partially
inactive mutant IL-1.beta., by fusing it to a nanobody recognizing
a cell surface receptor, can restore its activity on nanobody
target cells, probably by forced receptor interaction through a
membrane concentration effect. The fact that activation by
targeting can be accomplished using nanobodies recognizing
different classes of membrane proteins indicates broad
applicability of the "activation by targeting" concept.
[0040] Because these data provide proof of concept for the ability
of targeting mutant IL-1 family members to selected cell types,
restoring their activity on these target cells only, nanobodies are
produced that allow targeting IL-1 family members to
physiologically relevant IL-1.beta. target cells. In view of the
important role of IL-1 family members as T- and NK-cell activators,
the nanobodies are designed to specifically target IL-1 to T- and
NK-cell subsets. More specifically nanobodies targeting CCR6, which
are predominantly expressed on Th17 cells as well as nanobodies
targeting CD8 on cytotoxic T cells are developed and fused to the
members of the IL1-family, preferably IL-1.beta..
Example 3
Effect of IL-1.beta.-Nanobody Fusions on IL-17 Production by
Primary Human T Cells
[0041] Primary human T cells were isolated from buffy coats. First,
PBMC's were isolated by lymphoprep density gradient centrifugation
and incubated O/N with 0.5 ng/ml rhIL-2 for recovery. Next, T-cells
were isolated using the pan-T cell isolation kit (Miltenyi Biotec)
according to the manufacturer's instructions. Briefly, T cells were
resuspended (1.times.10.sup.6/ml) in RPMI-1640 supplemented with
10% FCS and CD3/CD28 activating microbeads (Miltenyi Biotec). Next,
cells (100 .mu.l/well) were plated in U-bottom 96-well plates and
stimulated for 96 hours with the indicated concentrations of
IL-1.beta. variants. After an additional 6 hours stimulation with
PMA/ionomycin (both at 100 nM), supernatants were recovered and
IL-17 levels were determined by Elisa (R&D Systems). Additional
cytokines are evaluated via Luminex technology.
[0042] For selected mutant IL-1.beta.-nanobody fusions (e.g. with a
nanobody targeting CCR6) target cell-specific IL-17 and IFN.gamma.
production are evaluated by intracellular staining using a flow
cytometric approach.
[0043] Also, to corroborate selectivity for the Th17 population,
binding to PBMC subpopulations is measured via double staining
using the Flag tag and selected CD markers, followed by flow
cytometric analysis.
[0044] Finally, in a clinically relevant in vitro model of human
Th17 cell function, the adjuvant activity of the
IL-1.beta.-nanobody fusions is assessed. In view of the need for
more efficacious vaccines against Bordetella pertussis (or
adjuvants for the existing vaccines), we determined whether the
selected fusion proteins enhance the human Th17 response in a
coculture model of naive T cells with B. pertussis-treated
monocyte-derived dendritic cells (MDDCs). Human MDDCs are isolated
from buffy coats (using the monocyte isolation kit II, Miltenyi
Biotec), treated with different ratios of B. pertussis for 48 hours
and then cocultured with naive allogeneic T cells for 12 days.
After restimulation with anti-CD3/anti-CD28, the cytokine profiles
in supernatants are determined using Elisa/Luminex technology (cfr.
supra).
Example 4
Effect of IL-1.beta.-Nanobody Fusions on CTLs
[0045] To assess whether IL-1.beta.-CD8 nanobody fusions can
specifically enhance the function of CD8+ T cells, human PBMC's are
isolated by lymphoprep density gradient centrifugation from buffy
coats and stimulated for 24 hours with CD3/CD28 activating
microbeads (Miltenyi Biotec) in combination with wt or mutant
IL1.beta.-CD8 Nb fusions. The effect of these fusion proteins on
CD8+ T cell activation is evaluated by performing intracellular
staining for active (phosphorylated) NF-.kappa.B and IFN.gamma.. In
addition, to investigate whether the IL-1.beta.-nanobody fusions
affect CTL degranulation, PBMC's (2.times.10.sup.6 cells/ml) are
differentiated for 48 hours in the presence of phytohaemagglutinin
(PHA, 1 .mu.g/ml) and IL-2 (100 IU/ml) in combination with
increasing doses of the IL-1.beta. fusion proteins. Next, to induce
degranulation, cells are stimulated for 3 hours with CD3/CD28
dynabeads and analysed by flow cytometry. Degranulation is measured
via detection of cell surface CD107a, a well-established marker for
natural killer activity. In all flow cytometric analyses on
leukocyte pools, anti-CD8 staining is included to allow monitoring
of the cell-type specificity of the IL-1.beta.-CD8 Nb effects.
[0046] Finally to assess whether the IL-1.beta.-CD8 nanobody
fusions promote anti-tumor activity in vivo, C57BL/6 mice are
injected subcutaneously with TC1 tumor cells, which produce the E6
and E7 antigenic oncoproteins from HPV16. This model was previously
used to demonstrate that IL-1.beta. promotes CD8+ T cell-mediated,
antigen-specific, anti-tumor responses (Ben-Sasson, 2013). Briefly,
mice are immunized four days after tumor injection with a vaccine
containing the HPV16E7.sub.49-57 peptide, combined with DOTAP and
LPS, and with our without WT or mutant IL-1.beta.-CD8 Nb fusions or
IL-1.beta.-GFP Nb fusions. Tumor size is monitored for 18 days
post-immunization.
Example 5
In Vivo Experiments--Vaccine Adjuvans Effect
[0047] In a first series of experiments C57BL/6 mice are treated
iv/ip with different doses of WT and mutant IL-1.beta.-nanobody
fusions and unfused IL-1.beta., to monitor acute toxicity. Venous
blood is collected at different times post treatment by tail
venopuncture and the cytokine profile in serum is determined by
Luminex assay. In addition, via flow cytometric analysis
intracellular cytokine levels (IL-17, IFN.gamma.) and activation of
IL-1R (as assessed by measuring phospho-NF-.kappa.B levels) are
determined in selected leukocyte subsets.
[0048] When optimal doses have been established, their adjuvant
activity is assessed in a murine vaccination protocol. Briefly,
C57BL/6 mice are immunized ip with acellular pertussis vaccine
(Pa). The Pa vaccine is composed of 5 .mu.g/mouse of purified
recombinant detoxified pertussis toxin (PT9K/129G)+filamentous
hemagglutinin (FHA) (composition according to Brereton et al.,
2011). 24 hours after immunization, selected mutant IL1.beta.-Nb or
PBS are administered ip or iv. Animals are boosted after 28 days.
One set of animals is sacrificed 14 days after the second
immunization and splenocytes are isolated and restimulated in vitro
with medium or FHA for 3 days. Cytokine levels in culture
supernatants (IL-17, IFN.gamma., IL-2, IL-10, IL-5, IL-4, etc.) are
determined via Luminex technology. A second set of mice is
challenged with B. pertussis on day 14 post-boost and sacrificed 2
h and 5 and 10 days post-challenge. Lungs are isolated and CFU in
lung homogenates will be quantified on Bordet-Gengou agar plates.
Cytokine levels in lung homogenates are determined as in splenocyte
supernatants.
[0049] In addition, blood is sampled (from the tail vene) before
immunization and then every 14 days for determination of B.
pertussis-specific IgG levels in serum.
Example 6
Direct Antitumor Effect of IL-1.beta.-Nanobody Fusions
[0050] To investigate the direct anti-tumour activity of selected
IL1-nanobody fusions, we use human A375 melanoma cells, which were
shown to be highly susceptible to IL-1-induced cytostatic effects
(Morinaga et al., 1990). To allow targeting of mutant IL-1 family
members to the A375 cells, a stable A375 clone expressing a cell
surface marker to which high-affinity nanobodies are already
available (i.e. CD20) is generated. The sensitivity of this cell
line, as compared to the parental A375 cells, to the
antiproliferative effect of the mutant IL1-nanobody fusion, is
investigated in vitro using the XTT proliferation assay. In vivo
anti-tumour activity of the mutant IL-1-nanobody fusions is
investigated using an A375 xenotransplant model. Briefly, athymic
nude mice are inoculated subcutaneously with A375 cells (parental
or expressing a surface marker for targeting) and tumor growth is
monitored for four weeks in animals treated with PBS or mutant
IL1-nanobody fusions.
Example 7
Extension of Principle to IL18: Application in Tumor Models
[0051] To assess the indirect anti-tumour activity of IL1 family
members, experiments are conducted to address the efficacy of
selected mutant IL-18-nanobody fusions using the Meth A syngeneic
mouse sarcoma model according to the protocol that was used
previously to demonstrate anti-tumour activity of IL-18 (Micallef
et al., 1997). IL18 variants used in these experiments consist of
mutant IL-18s fused to nanobodies targeting immune cells with
tumoricidal properties (i.e. CTLs, NK-cells). The mice are treated
with the construct, and a significant reduction of the tumor is
noted when compared to the mock treated control.
REFERENCES
[0052] Acosta-Rodriguez E V, Napolitani G, Lanzavecchia A, Sallusto
F. (2007) Interleukins 1beta and 6 but not transforming growth
factor-beta are essential for the differentiation of interleukin
17-producing human T helper cells. Nat Immunol. 8:942-9.
[0053] Allakhverdi Z, Smith D E, Comeau M R, Delespesse G. (2007)
Cutting edge: The ST2 ligand IL-33 potently activates and drives
maturation of human mast cells. J Immunol. 179:2051-4.
[0054] Ben-Sasson S Z, Caucheteux S, Crank M, Hu-Li J, Paul W E.
(2011) IL-1 acts on T cells to enhance the magnitude of in vivo
immune responses. Cytokine.56:122-5.
[0055] Ben-Sasson S Z, Hogg A, Hu-Li J, Wingfield P, Chen X, Crank
M, Caucheteux S, Ratner-Hurevich M, Berzofsky J A, Nir-Paz R, Paul
W E. (2013) IL-1 enhances expansion, effector function, tissue
localization, and memory response of antigen-specific CD8 T cells.
J Exp Med. 210:491-502.
[0056] Blake, A. W., McCartney, L., Flint, J., Bolam, D. N.,
Boraston, A. B., Gilbert, H. J. and Knox, J. P. (2006)
Understanding the biological rationale for the diversity of
cellulose-directed carbohydrate-binding molecules in prokaryotic
enzymes. J. Biol. Chem. 281, 29321-29329.
[0057] Bonilla W V, Frohlich A, Senn K, Kallert S, Fernandez M,
Johnson S, Kreutzfeldt M, Hegazy A N, Schrick C, Fallon P G,
Klemenz R, Nakae S, Adler H, Merkler D, Lohning M, Pinschewer D D.
(2012). The alarmin interleukin-33 drives protective antiviral
CD8.sup.+ T cell responses. Science. 335:984-9.
[0058] Brecht A., Gauglitz G., Polster J. (1993). Interferometric
immunoassay in a FIA-system--A sensitive and rapid approach in
label-free immunosensing. Biosens Bioelectron 8: 387-392.
[0059] Brereton C F, Sutton C E, Ross P J, Iwakura Y, Pizza M,
Rappuoli R, Lavelle E C, Mills K H. (2011). Escherichia coli
heat-labile enterotoxin promotes protective Th17 responses against
infection by driving innate IL-1 and IL-23 production. J Immunol.
2011 May 15; 186(10):5896-906.
[0060] Dimitrov, D. S. (2009) Engineered CH2 domains
(nanoantibodies). mAbs 1, 26-28.
[0061] Dinarello C A, Simon A, van der Meer J W. (2012). Treating
inflammation by blocking interleukin-1 in a broad spectrum of
diseases. Nat Rev Drug Discov. 11:633-52.
[0062] Dunne A, Ross P J, Pospisilova E, Masin J, Meaney A, Sutton
C E, Iwakura Y, Tschopp J, Sebo P, Mills K H. (2010). Inflammasome
activation by adenylate cyclase toxin directs Th17 responses and
protection against Bordetella pertussis. J Immunol. 185:1711-9.
[0063] Higgins S C, Jarnicki A G, Lavelle E C, Mills K H. TLR4
mediates vaccine-induced protective cellular immunity to Bordetella
pertussis: role of IL-17-producing T cells. J Immunol. 2006 Dec. 1;
177(11):7980-9.
[0064] Khader S A, Bell G K, Pearl J E, Fountain J J, Rangel-Moreno
J, Cilley G E, Shen F, Eaton S M, Gaffen S L, Swain S L, Locksley R
M, Haynes L, Randall T D, Cooper A M. (2007). IL-23 and IL-17 in
the establishment of protective pulmonary CD4+ T cell responses
after vaccination and during Mycobacterium tuberculosis challenge.
Nat Immunol. 2007 8:369-77.
[0065] Killar, L. M., Hatfield, C. A., Carding, S. R., Pan, M.,
Winterrowd, G. E. and Bottomly, K. (1989) In vivo administration of
interleukin 1 elecits an increased la antigen expression on B cells
throught the production of interleukin 4. Eur. J. Immunol. 19,
2205-2210.
[0066] Kinoshita, M., Miyazaki, H., Ono, S., Inatsu, A., Nakashima,
H., Tsujimoto, H., Shinomiya, N., Saitoh, D. and Seki, S. (2011).
Enhancement of neutrophil function by interleukin 18 therapy
protects burn-injuredf mice from methicillin-resistant
Staphylococcus aureus. Infect. Immun. 79, 2670-2680.
[0067] Kolmar, H. (2008) Alternative binding proteins: biological
activity and therapeutic potential of cysteine-knot miniproteins.
FEBS J. 275, 2684-2690.
[0068] Leung B P, Culshaw S, Gracie J A, Hunter D, Canetti C A,
Campbell C, Cunha F, Liew F Y, McInnes I B. (2001). A role for
IL-18 in neutrophil activation. J Immunol. 167:2879-86.
[0069] Loeffler M, Le'Negrate G, Krajewska M, Reed J C. (2008).
IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther.
15:787-94.
[0070] Micallef M J, Tanimoto T, Kohno K, Ikeda M, Kurimoto M.
(1997). Interleukin 18 induces the sequential activation of natural
killer cells and cytotoxic T lymphocytes to protect syngeneic mice
from transplantation with Meth A sarcoma. Cancer Res. ;
57:4557-63.
[0071] Morinaga Y, Hayashi H, Takeuchi A, Onozaki K. (1990).
Antiproliferative effect of interleukin 1 (IL-1) on tumor cells:
G0-G1 arrest of a human melanoma cell line by IL-1. Biochem Biophys
Res Commun. 173:186-92.
[0072] Nygren, P-A. (2008) Alternative binding proteins: affibody
binding proteins developed from a small three-helix bundle
scaffold. FEBS J. 275, 2668-2676.
[0073] Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A,
Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, et al. (1995).
Cloning of a new cytokine that induces IFN-gamma production by T
cells. Nature. 378:88-91.
[0074] Rangnekar V V, Waheed S, Rangnekar V M. (1992).
Interleukin-1-inducible tumor growth arrest is characterized by
activation of cell type-specific "early" gene expression programs.
J Biol Chem. 267:6240-8.
[0075] Robertson M J, Kirkwood J M, Logan T F, Koch K M, Kathman S,
Kirby L C, Bell W N, Thurmond L M, Weisenbach J, Dar M M. (2008). A
dose-escalation study of recombinant human interleukin-18 using two
different schedules of administration in patients with cancer. Clin
Cancer Res. 14:3462-9
[0076] Scatchard G. (1949). Ann New York Acad Sci 51, 660-72.
[0077] Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan
T K, Zurawski G, Moshrefi M, Qin J, Li X, Gorman D M, Bazan J F,
Kastelein R A. (2005). IL-33, an interleukin-1-like cytokine that
signals via the IL-1 receptor-related protein ST2 and induces T
helper type 2-associated cytokines. Immunity. 23:479-90.
[0078] Shaw M H, Kamada N, Kim Y G, N nez G. (2012).
Microbiota-induced IL-1.beta., but not IL-6, is critical for the
development of steady-state TH17 cells in the intestine. J Exp Med.
209:251-8.
[0079] Sims J E, Smith D E. The IL-1 family: regulators of
immunity. (2010). Nat Rev Immunol. 10:89-102.
[0080] Skerra, A. (2008) Alternative binding proteins:
anticalins--harnessing the structural plasticity of the lipocalin
ligand pocket to engineer novel binding activities. FEBS J. 275,
2677-2683.
[0081] Stump, M. T., Binz, H. K., Amstutz, P. (2008) DARPins: a new
generation of protein therapeutics. Drug iscov. Today 13,
695-701.
[0082] Sutton C, Brereton C, Keogh B, Mills K H, Lavelle E C.
(2006). A crucial role for interleukin (IL)-1 in the induction of
IL-17-producing T cells that mediate autoimmune encephalomyelitis.
J Exp Med. 203:1685-91.
[0083] Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N,
Kishimoto T, Okamura H, Nakanishi K, Akira S. (1998). Defective NK
cell activity and Th1 response in IL-18-deficient mice.
[0084] Immunity. 8:383-90.
[0085] Tramontano, A., Bianchi, E., Venturini, S., Martin, F.,
Pessi, A and Sollazzo, M. (1994) The making of the minibody: an
engineered beta-protein for the display of conformationally
constrained peptides. J. Mol. Recognition 7, 9-24.
[0086] Usui N, Mimnaugh E G, Sinha B K. (1991). A role for the
interleukin 1 receptor in the synergistic antitumor effects of
human interleukin 1 alpha and etoposide against human melanoma
cells. Cancer Res. 1991 51:769-74.
[0087] Vanden Berghe W, Plaisance S, Boone E, De Bosscher K,
Schmitz M L, Fiers W, Haegeman G. (1998). p38 and extracellular
signal-regulated kinase mitogen-activated protein kinase pathways
are required for nuclear factor-kappaB p65 transactivation mediated
by tumor necrosis factor. J Biol Chem. 273:3285-90.
[0088] Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C,
Wernery U, Muyldermans S, Lahoutte T, Caveliers V. (2011).
Preclinical screening of anti-HER2 nanobodies for molecular imaging
of breast cancer. FASEB J. 25:2433-46.
[0089] Wigginton J M, Lee J K, Wiltrout T A, Alvord W G, Hixon J A,
Subleski J, Back T C, Wiltrout R H. (2002). Synergistic engagement
of an ineffective endogenous anti-tumor immune response and
induction of IFN-gamma and Fas-ligand-dependent tumor eradication
by combined administration of IL-18 and IL-2. J Immunol.
169:4467-74.
[0090] Wilke C M, Bishop K, Fox D, Zou W. (2011). Deciphering the
role of Th17 cells in human disease. Trends Immunol. 32:603-11.
[0091] Ye P, Rodriguez F H, Kanaly S, Stocking K L, Schurr J,
Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, Shellito J
E, Bagby G J, Nelson S, Charrier K, Peschon J J, Kolls J K. (2001).
Requirement of interleukin 17 receptor signaling for lung CXC
chemokine and granulocyte colony-stimulating factor expression,
neutrophil recruitment, and host defense. J Exp Med.
194:519-27.
[0092] Zabeau L, Verhee A, Catteeuw D, Faes L, Seeuws S, Decruy T,
Elewaut D, Peelman F, Tavernier J. (2012). Selection of
non-competitive leptin antagonists using a random nanobody-based
approach. Biochem J. 441:425-34.
[0093] Zaki M H, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti
TD. (2010). IL-18 production downstream of the NIrp3 inflammasome
confers protection against colorectal tumor formation. J Immunol.
185:4912-20.
Sequence CWU 1
1
108144DNAArtificial SequencePrimer 1ccgactacgc tggcggcagt
gacggtgtca gaagcctgaa ctgc 44243DNAArtificial SequencePrimer
2ctggcggcag cgcccctgtc gctagcctga actgcaccct gcg 43339DNAArtificial
SequencePrimer 3gcggcagcgc ccctgtcgga agcttgaact gcaccctgc
39452DNAArtificial SequencePrimer 4cgctggcggc agtgcccctg tcagaagcgc
gaactgcacc ctgcgggaca gc 52552DNAArtificial SequencePrimer
5cgcccctgtc agaagcctga actgcggcgg ccgggacagc cagcagaaaa gc
52648DNAArtificial SequencePrimer 6agaagcctga actgcacact gggggacagc
cagcagaaaa gcctggtc 48730DNAArtificial SequencePrimer 7ccctgcggga
cagcgcgcag aaaagcctgg 30843DNAArtificial SequencePrimer 8ctgcaccctg
cgggacagct ggcagaaaag cctggtcatg agc 43937DNAArtificial
SequencePrimer 9ctgcgggaca gccaggggaa gagcctggtc atgagcg
371045DNAArtificial SequencePrimer 10gcaccctgcg ggacagccag
caggctagcc tggtcatgag cggcc 451149DNAArtificial SequencePrimer
11cagcagaaaa gcctggtcat ggggtacccc tacgagctga aggcactgc
491245DNAArtificial SequencePrimer 12gcccctacga gctgaaggca
ggtcatctgc agggccagga catgg 451338DNAArtificial SequencePrimer
13cgagctgaag gcactggctc ttcagggcca ggacatgg 381442DNAArtificial
SequencePrimer 14cctacgagct gaaggcactg ggtctgcagg gccaggacat gg
421529DNAArtificial SequencePrimer 15gctgaaggca ctggagctgc
agggccagg 291629DNAArtificial SequencePrimer 16agctgaaggc
actgaatctg cagggccag 291727DNAArtificial SequencePrimer
17ctgaaggcac tgcgtctgca gggccag 271848DNAArtificial SequencePrimer
18gcggccccta cgagctgaag gcagcgcatg cgcagggcca ggacatgg
481927DNAArtificial SequencePrimer 19ggcactgcat ctggagggcc aggacat
272038DNAArtificial SequencePrimer 20gaaggcactg catctgggtg
gccaggacat ggaacagc 382127DNAArtificial SequencePrimer 21gcactgcatc
tgctgggcca ggacatg 272247DNAArtificial SequencePrimer 22cgagctgaag
gcactgcatc tggggggcgg ggacatggaa cagcagg 472348DNAArtificial
SequencePrimer 23gcactgcatc tgcagggcgg ggccatggaa cagcaggtcg
tgttcagc 482454DNAArtificial SequencePrimer 24gcactgcatc tgcagggcca
ggacggggaa cagcaggtgg tgttcagcat gagc 542558DNAArtificial
SequencePrimer 25catggaacag caggtggtgt tcagcatgag cgccgtgcag
ggcgaggaaa gcaacgac 582656DNAArtificial SequencePrimer 26gcaggtcgtg
ttcagcatga gcgccgtgga gggcgaggaa agcaatgaca agatcc
562746DNAArtificial SequencePrimer 27ccgacttcac catgcaggcc
gtctccagcg gcggcagcag atctgg 462850DNAArtificial SequencePrimer
28gcatgagctt cgtggggggc aaggaaagca atgacaagat ccccgtggcc
502955DNAArtificial SequencePrimer 29gcagggcgag gaaagcggcg
gcaagatccc cgtggcccta ggcctgaaag agaag 553032DNAArtificial
SequencePrimer 30gaaagcaacg acaaggcccc cgtggccctg gg
323136DNAArtificial SequencePrimer 31gcaacgacaa gatccccgcg
gccctgggcc tgaaag 363255DNAArtificial SequencePrimer 32gcagctggaa
agcgtggatc ccaagaacta ccccgagaaa aagatggaaa aacgc
553349DNAArtificial SequencePrimer 33ccccaagaac taccccaagg
caaagatgga aaagcgcttc gtgttcaac 493455DNAArtificial SequencePrimer
34gcagctggaa agcgtggatc ccaagaacta ccccaaggac aagatggaaa aacgc
553546DNAArtificial SequencePrimer 35ccccaagaac taccccaagg
cagcgatgga aaaacgcttc gtgttc 463644DNAArtificial SequencePrimer
36aaaaacgctt cgtgttcaac agcatcgaga tcaacaacaa gctc
443741DNAArtificial SequencePrimer 37aaaaacgctt cgtgttcaac
cagatcgaga tcaacaacaa g 413842DNAArtificial SequencePrimer
38gcttcgtgtt caacaagatc tcgatcaaca acaagctcga gt
423939DNAArtificial SequencePrimer 39cttcgtgttc aacaagatca
agatcaacaa caagctcga 394053DNAArtificial SequencePrimer
40ggaaaaacgc ttcgtcttca acagcatctc gatcaacaac aagctcgagt tcg
534148DNAArtificial SequencePrimer 41cgcttcgtgt tcaacaagat
ctcgatcaac gccaagctcg agttcgag 484246DNAArtificial SequencePrimer
42caacaagatc gagatcaaca gcagcctcga attcgagagc gcccag
464350DNAArtificial SequencePrimer 43ccccaactgg tacatcagta
ctagtcaggc caagaatatg cccgtgttcc 504446DNAArtificial SequencePrimer
44cagcactagt caggccgagc agatgcccgt cttcctgggc ggcacc
464549DNAArtificial SequencePrimer 45catcagcact agtcaggcca
agcagatgcc cgtcttcctg ggcggcacc 494639DNAArtificial SequencePrimer
46gcggcagcgc ccctgtcgga agcttgaact gcaccctgc 394738DNAArtificial
SequencePrimer 47cgagctgaag gcactggctc ttcagggcca ggacatgg
384848DNAArtificial SequencePrimer 48gcggccccta cgagctgaag
gcagcgcatg cgcagggcca ggacatgg 484939DNAArtificial SequencePrimer
49gcggcagcgc ccctgtcgga agcttgaact gcaccctgc 395056DNAArtificial
SequencePrimer 50gcaggtcgtg ttcagcatga gcgccgtgga gggcgaggaa
agcaatgaca agatcc 565155DNAArtificial SequencePrimer 51gcagctggaa
agcgtggatc ccaagaacta ccccgagaaa aagatggaaa aacgc
555237DNAArtificial SequencePrimer 52ctgcgggaca gccaggggaa
gagcctggtc atgagcg 375356DNAArtificial SequencePrimer 53gcaggtcgtg
ttcagcatga gcgccgtgga gggcgaggaa agcaatgaca agatcc
565455DNAArtificial SequencePrimer 54gcagctggaa agcgtggatc
ccaagaacta ccccgagaaa aagatggaaa aacgc 555544DNAArtificial
SequencePrimer 55gcagttcagg cttctgacac cgtcactgcc gccagcgtag tcgg
445643DNAArtificial SequencePrimer 56cgcagggtgc agttcaggct
agcgacaggg gcgctgccgc cag 435739DNAArtificial SequencePrimer
57gcagggtgca gttcaagctt ccgacagggg cgctgccgc 395852DNAArtificial
SequencePrimer 58gctgtcccgc agggtgcagt tcgcgcttct gacaggggca
ctgccgccag cg 525952DNAArtificial SequencePrimer 59gcttttctgc
tggctgtccc ggccgccgca gttcaggctt ctgacagggg cg 526048DNAArtificial
SequencePrimer 60gaccaggctt ttctgctggc tgtcccccag tgtgcagttc
aggcttct 486130DNAArtificial SequencePrimer 61ccaggctttt ctgcgcgctg
tcccgcaggg 306243DNAArtificial SequencePrimer 62gctcatgacc
aggcttttct gccagctgtc ccgcagggtg cag 436337DNAArtificial
SequencePrimer 63cgctcatgac caggctcttc ccctggctgt cccgcag
376445DNAArtificial SequencePrimer 64ggccgctcat gaccaggcta
gcctgctggc tgtcccgcag ggtgc 456549DNAArtificial SequencePrimer
65gcagtgcctt cagctcgtag gggtacccca tgaccaggct tttctgctg
496645DNAArtificial SequencePrimer 66ccatgtcctg gccctgcaga
tgacctgcct tcagctcgta ggggc 456738DNAArtificial SequencePrimer
67ccatgtcctg gccctgaaga gccagtgcct tcagctcg 386842DNAArtificial
SequencePrimer 68ccatgtcctg gccctgcaga cccagtgcct tcagctcgta gg
426929DNAArtificial SequencePrimer 69cctggccctg cagctccagt
gccttcagc 297029DNAArtificial SequencePrimer 70ctggccctgc
agattcagtg ccttcagct 297127DNAArtificial SequencePrimer
71ctggccctgc agacgcagtg ccttcag 277248DNAArtificial SequencePrimer
72ccatgtcctg gccctgcgca tgcgctgcct tcagctcgta ggggccgc
487327DNAArtificial SequencePrimer 73atgtcctggc cctccagatg cagtgcc
277438DNAArtificial SequencePrimer 74gctgttccat gtcctggcca
cccagatgca gtgccttc 387527DNAArtificial SequencePrimer 75catgtcctgg
cccagcagat gcagtgc 277647DNAArtificial SequencePrimer 76cctgctgttc
catgtccccg ccccccagat gcagtgcctt cagctcg 477748DNAArtificial
SequencePrimer 77gctgaacacg acctgctgtt ccatggcccc gccctgcaga
tgcagtgc 487854DNAArtificial SequencePrimer 78gctcatgctg aacaccacct
gctgttcccc gtcctggccc tgcagatgca gtgc 547958DNAArtificial
SequencePrimer 79gtcgttgctt tcctcgccct gcacggcgct catgctgaac
accacctgct gttccatg 588056DNAArtificial SequencePrimer 80ggatcttgtc
attgctttcc tcgccctcca cggcgctcat gctgaacacg acctgc
568146DNAArtificial SequencePrimer 81ccagatctgc tgccgccgct
ggagacggcc tgcatggtga agtcgg 468250DNAArtificial SequencePrimer
82ggccacgggg atcttgtcat tgctttcctt gccccccacg aagctcatgc
508355DNAArtificial SequencePrimer 83cttctctttc aggcctaggg
ccacggggat cttgccgccg ctttcctcgc cctgc 558432DNAArtificial
SequencePrimer 84cccagggcca cgggggcctt gtcgttgctt tc
328536DNAArtificial SequencePrimer 85ctttcaggcc cagggccgcg
gggatcttgt cgttgc 368655DNAArtificial SequencePrimer 86gcgtttttcc
atctttttct cggggtagtt cttgggatcc acgctttcca gctgc
558749DNAArtificial SequencePrimer 87gttgaacacg aagcgctttt
ccatctttgc cttggggtag ttcttgggg 498855DNAArtificial SequencePrimer
88gcgtttttcc atcttgtcct tggggtagtt cttgggatcc acgctttcca gctgc
558946DNAArtificial SequencePrimer 89gaacacgaag cgtttttcca
tcgctgcctt ggggtagttc ttgggg 469044DNAArtificial SequencePrimer
90gagcttgttg ttgatctcga tgctgttgaa cacgaagcgt tttt
449141DNAArtificial SequencePrimer 91cttgttgttg atctcgatct
ggttgaacac gaagcgtttt t 419242DNAArtificial SequencePrimer
92actcgagctt gttgttgatc gagatcttgt tgaacacgaa gc
429339DNAArtificial SequencePrimer 93tcgagcttgt tgttgatctt
gatcttgttg aacacgaag 399453DNAArtificial SequencePrimer
94cgaactcgag cttgttgttg atcgagatgc tgttgaagac gaagcgtttt tcc
539548DNAArtificial SequencePrimer 95ctcgaactcg agcttggcgt
tgatcgagat cttgttgaac acgaagcg 489646DNAArtificial SequencePrimer
96ctgggcgctc tcgaattcga ggctgctgtt gatctcgatc ttgttg
469750DNAArtificial SequencePrimer 97ggaacacggg catattcttg
gcctgactag tactgatgta ccagttgggg 509846DNAArtificial SequencePrimer
98ggtgccgccc aggaagacgg gcatctgctc ggcctgacta gtgctg
469949DNAArtificial SequencePrimer 99ggtgccgccc aggaagacgg
gcatctgctt ggcctgacta gtgctgatg 4910039DNAArtificial SequencePrimer
100gcagggtgca gttcaagctt ccgacagggg cgctgccgc 3910138DNAArtificial
SequencePrimer 101ccatgtcctg gccctgaaga gccagtgcct tcagctcg
3810248DNAArtificial SequencePrimer 102ccatgtcctg gccctgcgca
tgcgctgcct tcagctcgta ggggccgc 4810339DNAArtificial SequencePrimer
103gcagggtgca gttcaagctt ccgacagggg cgctgccgc 3910456DNAArtificial
SequencePrimer 104ggatcttgtc attgctttcc tcgccctcca cggcgctcat
gctgaacacg acctgc 5610555DNAArtificial SequencePrimer 105gcgtttttcc
atctttttct cggggtagtt cttgggatcc acgctttcca gctgc
5510637DNAArtificial SequencePrimer 106cgctcatgac caggctcttc
ccctggctgt cccgcag 3710756DNAArtificial SequencePrimer
107ggatcttgtc attgctttcc tcgccctcca cggcgctcat gctgaacacg acctgc
5610855DNAArtificial SequencePrimer 108gcgtttttcc atctttttct
cggggtagtt cttgggatcc acgctttcca gctgc 55
* * * * *